These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27033185)

  • 1. Can we Monitor a Patient with Inflammatory Bowel Disease and Adapt Treatment without Endoscopy?
    Panes J; Ricart E
    Curr Drug Targets; 2018; 19(7):777-781. PubMed ID: 27033185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
    Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
    Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease monitoring in inflammatory bowel disease.
    Chang S; Malter L; Hudesman D
    World J Gastroenterol; 2015 Oct; 21(40):11246-59. PubMed ID: 26523100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease.
    Limketkai BN; Singh S; Jairath V; Sandborn WJ; Dulai PS
    Inflamm Bowel Dis; 2019 Oct; 25(11):1828-1837. PubMed ID: 31039246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimising monitoring in the management of Crohn's disease: a physician's perspective.
    Papay P; Ignjatovic A; Karmiris K; Amarante H; Milheller P; Feagan B; D'Haens G; Marteau P; Reinisch W; Sturm A; Steinwurz F; Egan L; Panés J; Louis E; Colombel JF; Panaccione R
    J Crohns Colitis; 2013 Sep; 7(8):653-69. PubMed ID: 23562672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease.
    Hoekman DR; Diederen K; Koot BG; Tabbers MM; Kindermann A; Benninga MA
    Eur J Pediatr; 2016 Oct; 175(10):1335-42. PubMed ID: 27573259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
    Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
    Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
    Jusué V; Chaparro M; Gisbert JP
    Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
    ; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
    J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
    Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
    Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging.
    Faubion WA; Fletcher JG; O'Byrne S; Feagan BG; de Villiers WJ; Salzberg B; Plevy S; Proctor DD; Valentine JF; Higgins PD; Harris JM; Diehl L; Wright L; Tew GW; Luca D; Basu K; Keir ME
    Am J Gastroenterol; 2013 Dec; 108(12):1891-900. PubMed ID: 24126633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.
    Mosli MH; Zou G; Garg SK; Feagan SG; MacDonald JK; Chande N; Sandborn WJ; Feagan BG
    Am J Gastroenterol; 2015 Jun; 110(6):802-19; quiz 820. PubMed ID: 25964225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of a Patient-reported Score to Screen for Mucosal Inflammation in Inflammatory Bowel Disease.
    de Jong MJ; Roosen D; Degens JHRJ; van den Heuvel TRA; Romberg-Camps M; Hameeteman W; Bodelier AGL; Romanko I; Lukas M; Winkens B; Markus T; Masclee AAM; van Tubergen A; Jonkers DMAE; Pierik MJ
    J Crohns Colitis; 2019 Apr; 13(5):555-563. PubMed ID: 30476099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease.
    Pinto-Lopes P; Melo F; Afonso J; Pinto-Lopes R; Rocha C; Melo D; Macedo G; Dias CC; Carneiro F; Magro F;
    Clin Transl Gastroenterol; 2021 Mar; 12(3):e00320. PubMed ID: 33704099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
    Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ
    J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum leucine-rich alpha-2 glycoprotein and calprotectin in children with inflammatory bowel disease: A multicenter study in Japan.
    Yasuda R; Arai K; Kudo T; Nambu R; Aomatsu T; Abe N; Kakiuchi T; Hashimoto K; Sogo T; Takahashi M; Etani Y; Kato K; Yamashita Y; Mitsuyama K; Mizuochi T
    J Gastroenterol Hepatol; 2023 Jul; 38(7):1131-1139. PubMed ID: 36880154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.